Scientific Data on Epratuzumab in Systemic Lupus Erythematosus to be Presented at EULAR 2014

Scientific Data on Epratuzumab in Systemic Lupus Erythematosus to be Presented
at EULAR 2014

MORRIS PLAINS, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc.,
(Nasdaq:IMMU) today announced that scientific data on epratuzumab, an
investigational therapy for the treatment of systemic lupus erythematosus
(SLE), also known as lupus, will be presented at the European League Against
Rheumatism (EULAR) 2014 Annual Congress to be held in Paris, France, from June
11 – 14, 2014.

Epratuzumab is an investigational medicine in Phase III clinical development
for the treatment of SLE. Epratuzumab is a monoclonal antibody that targets
CD22 - a B-cell-specific protein that regulates B-cell activity.^1,2
Epratuzumab is not approved for the treatment of SLE by any regulatory
authority worldwide.

Immunomedics has granted UCB exclusive worldwide rights to develop, market,
and sell epratuzumab for all autoimmune disease indications.

Following is a guide to the presentations being given as posters or abstracts
at EULAR 2014:

Investigational studies of epratuzumab in systemic lupus erythematosus

1. [THU0023]: Correlation of Laboratory and Clinical Parameters with British
Isles Lupus Assessment Group Response in an Open-Label Extension Study of
Epratuzumab in Systemic Lupus Erythematosus
Furie, R. A. et al.

  *Date/Time: Thursday June 12th; 11:45 – 13:30
  *Session Info: Poster session, Poster Area, Level 1
  *Date/Time: Friday June 13th; 12:00 – 13:15
  *Session Info: Poster Tour, Level 2

2. [FRI0383]: Safety, Pharmacokinetics, and Pharmacodynamics of Epratuzumab in
Japanese Patients with Moderate-to-Severe Systemic Lupus Erythematosus:
Results from a Phase 1/2 Study
Yamamoto, J. et al.

  *Date/Time: Friday June 13th; 11:45 – 13:30
  *Session Info: Poster Session, Poster Area D, Level 4

3. [AB0023]: In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting
Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
Brandl, C. et al.

  *Abstract book

Systemic lupus erythematosus

4. [SAT0101]: A 'Real-World' Characterization of 'Moderate-to-severe' Systemic
Lupus Erythematosus
Strand, V. et al.

  *Date/Time: Saturday June 14th; 10:15 – 12:00
  *Session Info: Poster Session, Poster Area A, Level 1

5. [AB1117]: Burden of Disease in Systemic Lupus Erythematosus Patients
Treated with Corticosteroids
Strand, V. et al.

  *Abstract book

6. [AB1116]: Treatment of Patients with 'Moderate-to-severe' Systemic Lupus
Strand, V. et al.

  *Abstract book


1.Sanz I. & Lee F. Eun-Hyung. B cells as therapeutic targets in SLE. Nat.
    Rev. Rheumatology; 6. 2010; 326-337.
2.Walker J. & Smith K. CD22: an inhibitory enigma. Immunology; 123. 2008;

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing
monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune disorders and other serious diseases. Immunomedics' advanced
proprietary technologies allow the Company to create humanized antibodies that
can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these
technologies, Immunomedics has built a pipeline of nine clinical-stage product
candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB),
who has worldwide rights in non-cancer indications to Immunomedics' Phase III
product candidate, epratuzumab. UCB expects Phase III data in systemic lupus
erythematosus (SLE) in the first quarter of 2015. Immunomedics is exploring
epratuzumab in oncology in collaboration with outside cancer study groups.
Immunomedics' most advanced wholly owned candidate is ^90Y-clivatuzumab
tetraxetan, which is in an ongoing Phase III registration trial in patients
with pancreatic cancer. Immunomedics' portfolio of wholly owned product
candidates also includes antibody-drug conjugates (ADCs) that are designed to
deliver a specific payload of a chemotherapeutic directly to the tumor while
reducing overall toxicity effects that typically occur when these
chemotherapeutic agents are dosed alone.Immunomedics' most advanced ADCs are
IMMU-132 and IMMU-130, which are in Phase I/II trials for a number of solid
tumors and metastatic colorectal cancer (mCRC), respectively. Immunomedics
also has a number of other product candidates that target solid tumors and
hematologic malignancies, as well as other diseases, in various stages of
clinical and pre-clinical development. These include bispecific antibodies
which have application as T-cell redirecting immunotherapies targeting cancers
and infectious diseases as well as next-generation therapies in cancer and
autoimmune disease. Immunomedics creates these bispecific antibodies using its
patented DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The Company
believes that its portfolio of intellectual property, which includes
approximately 248 active patents in the United States and more than 400
foreign patents, protects its product candidates and
technologies.Immunomedics' strength in intellectual property has resulted in
the top-4 ranking in the January 2014 Patent Board scorecard in the
Biotechnology industry. For additional information on the Company, please
visit its website at The information on its website does
not, however, form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials (including the funding therefor, outcomes, timing or associated costs),
out-licensing arrangements (including the timing and amount of contingent
payments), forecasts of future operating results, potential collaborations,
and capital raising activities, involve significant risks and uncertainties
and actual results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are not limited
to, new product development (including clinical trials outcome and regulatory
requirements/actions), our dependence on UCB for the further development of
epratuzumab for non-cancer indications, risks associated with the outcome of
pending litigation, competitive risks to marketed products and availability of
required financing and other sources of funds on acceptable terms, if at all,
as well as the risks discussed in the Company's filings with the Securities
and Exchange Commission.The Company is not under any obligation, and the
Company expressly disclaims any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future
events or otherwise.

CONTACT: Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.